This is the authors' abstract. We don't add key points for this paper.
Background: Myeloproliferative neoplasms (MPN) are broadly divided by the presence or absence of the Philadelphia chromosome (Ph), with its presence considered a major marker of chronic myelogenous leukemia (CML). The co-occurence of a Ph-negative and Ph-positive MPN is a rare phenomenon with potentially significant prognostic and treatment implications, but there is a paucity of literature with regard to this co-occurrence and its subsequent management. Additionally, these unusual cases provide a lens through which one can better understand hematopoietic clonal dynamics. With progressive adoption of next-generation sequencing, the discovery of this co-occurrence will likely become more common with time. Case presentation: Herein, we present three separate cases of concomitant Ph-positive and Ph-negative MPN, their implications with respect to clonality, and discuss potential therapeutic approaches. Conclusions: Though the co-occurence of a Ph-negative and Ph-positive MPN is a rare phenomenon, it is most prevalent with JAK2 + MPN, seen in 0.4% of cases. This co-occurrence will likely become more prevalent over time with the progressive adoption of next-generation sequencing techniques and detection of subclinical clones. Cases of monoclonality and polyclonality have been shown to be responsible for the development of MPN co-occurrence. The development of unexplained new marrow fibrosis, leukocytosis, or thrombocytosis in previously well-controlled MPN should prompt evaluation for concomitant CML or other Ph-negative MPN, including systemic mastocytosis. Treatment resistance to TKI in CML, particularly in the absence of an identifiable resistance mutation, may be suggestive of developing JAK2-positivity.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Reap et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: